Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An increased level of Lp(a) lipoprotein has been identified as a risk factor for coronary artery disease that is highly heritable. The genetic determinants of the Lp(a) lipoprotein level and their relevance for the risk of coronary disease are incompletely understood. METHODS: We used a novel gene chip containing 48,742 single-nucleotide polymorphisms (SNPs) in 2100 candidate genes to test for associations in 3145 case subjects with coronary disease and 3352 control subjects. Replication was tested in three independent populations involving 4846 additional case subjects with coronary disease and 4594 control subjects. RESULTS: Three chromosomal regions (6q26-27, 9p21, and 1p13) were strongly associated with the risk of coronary disease. The LPA locus on 6q26-27 encoding Lp(a) lipoprotein had the strongest association. We identified a common variant (rs10455872) at the LPA locus with an odds ratio for coronary disease of 1.70 (95% confidence interval [CI], 1.49 to 1.95) and another independent variant (rs3798220) with an odds ratio of 1.92 (95% CI, 1.48 to 2.49). Both variants were strongly associated with an increased level of Lp(a) lipoprotein, a reduced copy number in LPA (which determines the number of kringle IV-type 2 repeats), and a small Lp(a) lipoprotein size. Replication studies confirmed the effects of both variants on the Lp(a) lipoprotein level and the risk of coronary disease. A meta-analysis showed that with a genotype score involving both LPA SNPs, the odds ratios for coronary disease were 1.51 (95% CI, 1.38 to 1.66) for one variant and 2.57 (95% CI, 1.80 to 3.67) for two or more variants. After adjustment for the Lp(a) lipoprotein level, the association between the LPA genotype score and the risk of coronary disease was abolished. CONCLUSIONS: We identified two LPA variants that were strongly associated with both an increased level of Lp(a) lipoprotein and an increased risk of coronary disease. Our findings provide support for a causal role of Lp(a) lipoprotein in coronary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, genetic studies found a causal link between elevated Lp(a) levels and a higher risk for CVD diseases,[184–189] and vice versa [190].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [185]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“[Statement]Hyper-Lp(a)-lipoproteinemia is a risk factor for ASCVD. (Evidence level: E-1a)”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [227]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We found the association between LDLR genotype and Lp(a) levels remained significant after accounting for the rs10455872 genotype that tags a narrower range of LPA alleles10, but we could not directly assess LPA KIV2 copy number variants in the UKBB cohort to assess for a difference between groups.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Multiple genome-wide association studies (GWAS) did not find an association between Lp(a) levels and common variants at the LDLR locus10,46,47, but a recent GWAS of 371,212 individuals in the UK Biobank did48.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Higher plasma Lp(a) concentrations are associated with an increased risk of ASCVD, but it appears to be a much weaker risk factor for most people than LDL-C [72,73].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [73]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Genomic Control for Association Studies
Devlin, B., & Roeder, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00997.x · Cited by 3,162
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194
Genomewide Association Analysis of Coronary Artery Disease
Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R. J., Meitinger, T., Braund, P., Wichmann, H.-E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072366 · Cited by 2,044
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction
Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., Jonasdottir, A., Sigurdsson, A., Baker, A., Palsson, A., et al. (2007) · Science · doi:10.1126/science.1142842 · Cited by 1,594
A Common Allele on Chromosome 9 Associated with Coronary Heart Disease
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., Hinds, D. A., Pennacchio, L. A., Tybjaerg-Hansen, A., Folsom, A. R., et al. (2007) · Science · doi:10.1126/science.1142447 · Cited by 1,587
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Self-citationCommon variants at 30 loci contribute to polygenic dyslipidemia
Kathiresan, S., Willer, C. J., Peloso, G. M., Demissie, S., Musunuru, K., Schadt, E. E., Kaplan, L., Bennett, D., Li, Y., Tanaka, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.291 · Cited by 1,364
Self-citation
Research works printed but not linked: 1
- Siekmeier R, 1996, Lab Medizin, 20, 294
Cited by
Items 201–300 of 1,004
Genetics: Implications for Prevention and Management of Coronary Artery Disease
Assimes, T. L., & Roberts, R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.039 · Cited by 126
“Well-powered studies using this array firmly established associations between CAD and genetic variants in LPA, the gene encoding lipoprotein(a), and confirmed several early GWAS discoveries for CAD (9p21, COL4A1/COL4A2, ZC3HC1, and CYP17A1) (73,74).”
BackgroundResultInfluentialLipoprotein (a) and diabetes mellitus
Lamina, C., & Ward, N. C. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.016 · Cited by 120
Meyer, N. J., Li, M., Feng, R., Bradfield, J. P., Gallop, R., Bellamy, S. L., Fuchs, B. D., Lanken, P. N., Albelda, S. Μ., Rushefski, M., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201005-0701oc · Cited by 120
“Previous reports using this array have used a thresholds of 1 3 1025, 5 3 1025, and 1 3 1026 (36, 39, 40), at times without a replication population (39).”
BackgroundDyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality
Graham, I. M., Cooney, M. T., Bradley, D., Dudina, A. L., & Reiner, Ž. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0313-7 · Cited by 121
Farnesoid X receptor represses hepatic human APOA gene expression
Chennamsetty, I., Claudel, T., Kostner, K. M., Baghdasaryan, A., Kratky, D., Levak-Frank, S., Frank, S., Gonzalez, F. J., Trauner, M., & Kostner, G. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45277 · Cited by 112
Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies
Kessler, T., & Schunkert, H. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.04.001 · Cited by 123
“It was unraveled independently by 3 research consortia at the same time (20–23), and together with the LPA locus, represents the locus with the strongest effect on CAD risk (24).”
BackgroundClinical Trial Design for Lipoprotein(a)-Lowering Therapies
Malick, W. A., Goonewardena, S. N., Köenig, W., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.033 · Cited by 116
Carotid plaque formation and serum biomarkers
Hermus, L., Lefrandt, J. D., Tio, R. A., Breek, J. C., & Zeebregts, C. J. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.013 · Cited by 113
Yeang, C., Hung, M., Byun, Y. S., Clopton, P., Yang, X., Witztum, J. L., & Tsimikas, S. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.01.005 · Cited by 114
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
Brandts, J., & Ray, K. K. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00860-8 · Cited by 119
The Association Between Circulating Lipoprotein(a) and Type 2 Diabetes: Is It Causal?
Ye, Z., Haycock, P. C., Gurdasani, D., Pomilla, C., Boekholdt, S. M., Tsimikas, S., Khaw, K.-T., Wareham, N. J., Sandhu, M. S., & Forouhi, N. G. (2014) · Diabetes · doi:10.2337/db13-1144 · Cited by 105
“It is known that the rare allele of rs10455872 in the intron 25 of LPA gene was inversely correlated with KIV-2 repeats (15).”
BackgroundResultEstablished and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Hopewell, J. C., Parish, S., Offer, A., Link, E., Clarke, R., Lathrop, M., Armitage, J., Collins, R., & on behalf of the MRC/BHF Heart Protection Study Collaborative Group (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs344 · Cited by 106
“02) and the sum of the minor alleles in the two SNPs was used to construct an LPA genotype score (as had been done previously for associations with coronary disease risk).(27) Higher LPA genotype scores were associated with smaller proportional lipid reductions but higher off-statin lipid levels, and with slightly sma…”
MethodSelf-citationThe Role of Lipids and Lipoproteins in Atherosclerosis
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W., Doran, A. C., & Vickers, K. C. (2015) · Europe PMC (PubMed Central) · Cited by 153
Mondo-Mlx Mediates Organismal Sugar Sensing through the Gli-Similar Transcription Factor Sugarbabe
Mattila, J., Havula, E., Suominen, E., Teesalu, M., Surakka, I. L., Hynynen, R., Kilpinen, H., Väänänen, J., Hovatta, I., Käkelä, R., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.081 · Cited by 114
“Moreover, lipoprotein(a) (LPA) is strongly associated with increased risk of coronary artery disease (Clarke et al., 2009), which is causally related to high circulating triglycerides (Do et al., 2013).”
BackgroundLipoprotein(a) catabolism: a case of multiple receptors
McCormick, S. P. A., & Schneider, W. J. (2019) · Pathology · doi:10.1016/j.pathol.2018.11.003 · Cited by 107
Dyslipidemia in women: etiology and management
Toth, P. P., & Phan, B. A. P. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s38133 · Cited by 124
“49 The 13 trials in their analysis included 17,891 women, with one third having a diagnosis of CHD.”
InfluentialSevere hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe
Thompson, G. R., Catapano, A. L., Saheb, S., Atassi, M., Barbir, M., Eriksson, M., Paulweber, B., Sijbrands, E. J. G., Stalenhoef, A. F. H., & Parhofer, K. G. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283402f53 · Cited by 107
France, M. W., Rees, A., Datta, D. B. N., Thompson, G. R., Capps, N. E., Ferns, G. A., Ramaswami, U., Seed, M., Neely, D., Cramb, R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.017 · Cited by 107
Lipoprotein(a): more interesting than ever after 50 years
Dubé, J. B., Boffa, M. B., Hegele, R. A., & Koschinsky, M. L. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835111d8 · Cited by 105
“[12] described particularly strong and independent associations between CHD and two LPA variants, namely rs10455872, which is a noncoding intronic SNP, and rs3798220, which is a missense variant encoding an amino acid substitution (Ile4399Met) in the apo(a) protease-like domain.”
BackgroundAntisense oligonucleotides for the treatment of dyslipidaemia
Visser, M. E., Witztum, J. L., Stroes, E. S. G., & Kastelein, J. J. P. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs084 · Cited by 103
“In addition, an extensive body of evidence, including a number of so-called Mendelian randomization studies, has now substantiated that an elevated Lp(a) level is a major and independent CVD risk factor.(38) However, evidence that lowering Lp(a) levels is beneficial with respect to CVD prevention is not yet available,…”
BackgroundZewinger, S., Kleber, M. E., Tragante, V., McCubrey, R. O., Schmidt, A. F., Direk, K., Laufs, U., Werner, C., Koenig, W., Rothenbacher, D., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30096-7 · Cited by 101
Lipoprotein(a), Cardiovascular Disease, and Contemporary Management
Jacobson, T. A. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.09.003 · Cited by 114
Arnold, M., Schweizer, J., Nakas, C. T., Schütz, V., Westphal, L. P., Inauen, C., Pokorny, T., Luft, A. R., Leichtle, A. B., Arnold, M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab081 · Cited by 108
Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk
Langsted, A., Kamstrup, P. R., & Nordestgaard, B. G. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.01.049 · Cited by 103
Identification of CAD candidate genes in GWAS loci and their expression in vascular cells
Erbilgin, A., Civelek, M., Romanoski, C. E., Pan, C., Hagopian, R., Berliner, J. A., & Lusis, A. J. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m037085 · Cited by 102
Davies, R. W., Dandona, S., Stewart, A. F. R., Chen, L., Ellis, S. G., Wilson Tang, W. H., Hazen, S. L., Roberts, R., McPherson, R., & Wells, G. A. (2010) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.110.946269 · Cited by 102
Genetic Susceptibility Contributing to Periodontal and Cardiovascular Disease
Aarabi, G., Zeller, T., Seedorf, H., Reissmann, D. R., Heydecke, G., Schäefer, A. S., & Seedorf, U. (2017) · Journal of Dental Research · doi:10.1177/0022034517699786 · Cited by 111
“In addition, strong associations with CAD and MI were identified on chromosome 6q26 within the lipoprotein(a) gene (LPA) by a combination of GWASs and large-scale candidate gene studies (Clarke et al. 2009).”
BackgroundSelf-citationLipoprotein(a) and Cardiovascular Risk Prediction Among Women
Cook, N. R., Mora, S., & Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.060 · Cited by 98
“genetic variants associated with elevated Lp(a) associate with vascular events (3,4).”
BackgroundThe PCSK9 revolution: Current status, controversies, and future directions
Warden, B. A., Fazio, S., & Shapiro, M. D. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.05.007 · Cited by 100
Lipoprotein(a)—The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation
Ugovšek, S., & Šebeštjen, M. (2021) · Biomolecules · doi:10.3390/biom12010026 · Cited by 98
“Among these SNPs, rs10455872 and rs3798220 have the most influence on Lp(a) levels [4], as they explain 36% of the variation in Lp(a) levels [8].”
BackgroundInfluentialde Boer, L. M., Hof, M. H. P., Wiegman, A., Stroobants, A. K., Kastelein, J. J. P., & Hutten, B. A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.004 · Cited by 110
Georgakis, M. K., & Gill, D. (2021) · Stroke · doi:10.1161/strokeaha.120.032617 · Cited by 107
The Brussels International Declaration on Lipoprotein(a) Testing and Management
Kronenberg, F., Bedlington, N., Ademi, Z., Geantă, M., Silberzahn, T., Rijken, M., Kaal, A., Harada‐Shiba, M., Chen, Z., Thanassoulis, G., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119218 · Cited by 105
Ding, L., Song, A., Dai, M., Xu, M., Sun, W., Xu, B., Sun, J., Wang, T., Xu, Y., Lu, J., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p049015 · Cited by 96
Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?
Enkhmaa, B., Petersen, K. S., Kris-Etherton, P. M., & Berglund, L. (2020) · Nutrients · doi:10.3390/nu12072024 · Cited by 94
Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk
Mehta, A., Virani, S. S., Ayers, C. R., Sun, W., Hoogeveen, R. C., Rohatgi, A., Berry, J. D., Joshi, P. H., Ballantyne, C. M., & Khera, A. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.06.040 · Cited by 99
Lipoprotein(a) and Cardiovascular Disease in Chinese Population
Li, J., Ma, C.-S., Zhao, D. H., Yan, X.-W., Li, J., Ma, C., Zhao, D. H., Yan, X.-W., Ye, P., Chen, H., et al. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.08.015 · Cited by 103
“Several observational studies and genomics studies have demonstrated that increased Lp(a) levels are an independent risk factor for CAD.”
MethodInfluentialNew therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
Norata, G. D., Ballantyne, C. M., & Catapano, A. L. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht088 · Cited by 99
“Major advances in understanding the causal role of elevated Lp(a) in premature CVD have been achieved.45 Although the benefits of lowering Lp(a) per se are still not demonstrated, a number of clinical and experimental studies, including mendelian randomization studies, indicate that this lipoprotein is causal in CVD.4…”
BackgroundTargeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.070 · Cited by 99
Zekavat, S. M., Ruotsalainen, S., Handsaker, R. E., Alver, M., Bloom, J., Poterba, T., Seed, C., Ernst, J., Chaffin, M., Engreitz, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04668-w · Cited by 98
Qi, Q., Workalemahu, T., Zhang, C., Hu, F. B., & Qi, L. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr350 · Cited by 96
“60).(8) Our study had 89% statistical power to detect such an effect size, assuming that the association is the same between the diabetic and the general population.”
BackgroundResultInfluentialBiomarkers of Calcific Aortic Valve Disease
Small, A., Kiss, D., Giri, J., Anwaruddin, S., Siddiqi, H., Guerraty, M., Chirinos, J. A., Ferrari, G., & Rader, D. J. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.308615 · Cited by 91
Current therapies for lowering lipoprotein (a)
van Capelleveen, J. C., van der Valk, F. M., & Stroes, E. G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r053066 · Cited by 97
Lipoprotein(a) and Cardiovascular Diseases ― Revisited ―
Jang, A. Y., Han, S. H., Sohn, I. S., Oh, P. C., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0051 · Cited by 105
Nissen, S. E., Wolski, K., Watts, G. F., Koren, M. J., Fok, H., Nicholls, S. J., Rider, D. A., Cho, L., Romano, S., Melgaard, C., et al. (2024) · JAMA · doi:10.1001/jama.2024.4504 · Cited by 90
Thanassoulis, G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r051870 · Cited by 94
Cardiovascular Disease: An Introduction
Thiriet, M. (2018) · Biomathematical and biomechanical modeling of the circulatory and ventilatory systems · doi:10.1007/978-3-319-89315-0_1 · Cited by 104
PhenX: a toolkit for interdisciplinary genetics research
Stover, P. J., Harlan, W. R., Hammond, J. A., Hendershot, T., & Hamilton, C. M. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283377395 · Cited by 94
Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints
Jarlborg, M., & Gabay, C. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155742 · Cited by 104
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31950-6 · Cited by 94
Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease
Sjaarda, J., Gerstein, H., Chong, M., Yusuf, S., Meyre, D., Anand, S. S., Hess, S., & Paré, G. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.067 · Cited by 94
“Four of these 6 (lipoprotein(a), apolipoprotein E, apolipoprotein C3, and interleukin-6 receptor) have been previously linked to CAD in many studies (6,8,16,17), consistent with our findings.”
ResultGessi, V., Marcucci, R., Gianni, M., Grandi, A. M., Franchini, M., & Dentali, F. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1598002 · Cited by 94
Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options
Likozar, A. R., Zavrtanik, M., & Šebeštjen, M. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1775287 · Cited by 102
“Lifestyle modifications are unlikely to have any effects on Lp(a) levels because of the primary genetic basis [24].”
BackgroundInfluentialImpact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
Parish, S., Hopewell, J. C., Hill, M. R., Marcovina, S., Valdes-Marquez, E., Haynes, R., Offer, A., Pedersen, T. R., Baigent, C., Collins, R., et al. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.117.001696 · Cited by 93
Self-citationLPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins
Wei, W., Li, X., Feng, Q., Kubo, M., Kullo, I. J., Peissig, P. L., Karlson, E. W., Jarvik, G. P., Lee, M. T. M., Shang, N., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.031356 · Cited by 96
“In a previous study of 1,822 individuals, the minor allele G of rs10455872 was associated with an increase in circulating Lp(a) levels of approximately 25%.(40) Plasma Lp(a) level is an independent predictor for CHD.”
BackgroundInfluentialFaghihnia, N., Tsimikas, S., Miller, E. R., Witztum, J. L., & Krauss, R. M. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m005769 · Cited by 90
Lipoprotein(a): A missing culprit in the management of athero‐thrombosis?
Ferretti, G., Bacchetti, T., Johnston, T. P., Banach, M., Pirro, M., & Sahebkar, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26050 · Cited by 98
“The other SNP, rs10455872, is intronic (Clarke et al., 2009).”
Pan, Y., Li, H., Wang, Y., Meng, X., & Wang, Y. (2019) · Stroke · doi:10.1161/strokeaha.119.026872 · Cited by 87
“The 2 SNPs (rs10455872 and rs3798220) together explained 36% of variation in Lp(a) concentrations.(19) The MR analysis required that the SNPs in the instruments were in linkage equilibrium.”
BackgroundManagement of residual risk after statin therapy
Reith, C. A., & Armitage, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.018 · Cited by 95
The metabolism of lipoprotein (a): an ever-evolving story
Reyes-Soffer, G., Ginsberg, H. N., & Ramakrishnan, R. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r077693 · Cited by 88
Schachtl-Riess, J. F., Kheirkhah, A., Grüneis, R., Di Maio, S., Schoenherr, S., Streiter, G., Losso, J. L., Paulweber, B., Eckardt, K.-U., Köttgen, A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.037 · Cited by 81
Lamon-Fava, S., Marcovina, S. M., Albers, J. J., Kennedy, H., DeLuca, C., White, C. C., Cupples, L. A., McNamara, J. R., Seman, L. J., Bongard, V., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m012526 · Cited by 90
Cao, J., Steffen, B. T., Budoff, M. J., Post, W. S., Thanassoulis, G., Kestenbaum, B. R., McConnell, J. P., Warnick, R., Guan, W., & Tsai, M. Y. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306683 · Cited by 95
Lipoprotein(a): Knowns, unknowns and uncertainties
Ruscica, M., Sirtori, C. R., Corsini, A., Watts, G. F., & Sahebkar, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105812 · Cited by 96
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kim, K., Ginsberg, H. N., & Choi, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0198 · Cited by 80
“A case-control study showed that two LPA variants were significantly associated with an increased plasma Lp(a) level and an increased risk of coronary disease [111].”
BackgroundWilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.007 · Cited by 97
“Moreover, individual studies in different populations (eg, primary vs secondary prevention) have arrived at different cut points ($30 mg/dL and $50 mg/dL, respectively).(37) It is unlikely that these observations reflect differences in the underlying pathobiology of Lp(a).”
BackgroundObesity, weight loss and conditional cardiovascular risk factors
Tzotzas, T., Evangelou, P., & Kiortsis, D. N. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00807.x · Cited by 86
“In addition, recent studies have identified new ‘emerging’ factors of which the association with coronary heart disease (CHD) needs further confirmation (2).”
BackgroundLipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy
Nicholls, S. J., Tang, W. H. W., Scoffone, H. M., Brennan, D. M., Hartiala, J., Allayee, H., & Hazen, S. L. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m008961 · Cited by 89
Liu, H., Cao, Y., Jin, J., Zhang, H., Hua, Q., Li, Y., Guo, Y., Zhu, C., Wu, N., Xu, R., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014581 · Cited by 88
Guo, Y., Lanktree, M. B., Taylor, K. C., Hakonarson, H., Lange, L. A., Keating, B. J., & The IBC 50K SNP array BMI Consortium (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds396 · Cited by 85
“Robust associations have been shown on the IBC array for a range of phenotypes including coronary artery disease (20,21), heart failure (22,23), lipids (24), height (25) and T2D (26).”
BackgroundMethodThe Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering
O’Donoghue, M. L., Rosenson, R. S., López, J. A. G., Lepor, N. E., Baum, S. J., Stout, E., Gaudet, D., Knüsel, B., Kuder, J., Murphy, S. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.058 · Cited by 91
Saeed, A., Sun, W., Agarwala, A., Virani, S. S., Nambi, V., Coresh, J., Selvin, E., Boerwinkle, E., Jones, P. H., Ballantyne, C. M., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.12.022 · Cited by 94
Nomura, A., Won, H.-H., Khera, A. V., Takeuchi, F., Ito, K., McCarthy, S., Emdin, C. A., Klarin, D., Natarajan, P., Zekavat, S. M., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.311145 · Cited by 86
“…Infarction Peptide Study (Leicester), 26 the Lübeck Myocardial Infarction Study (Lubeck), 27 the Ottawa Heart Study (OHS), 28 the Precocious Coronary Artery Disease Study (PROCARDIS), 29 the Pakistan Risk of Myocardial Infarction Study (PROMIS), 30 and the Registre Gironi del COR (REGICOR) Study.”
BackgroundSelf-citationGenetics of Coronary Artery Disease
Musunuru, K., & Kathiresan, S. (2010) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082509-141637 · Cited by 83
Zhang, Y., Jin, J., Cao, Y., Zhang, H., Guo, Y., Wu, N., Zhu, C., Gao, Y., Hua, Q., Li, Y., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01083-8 · Cited by 86
Kamstrup, P. R., Hung, M.-Y., Witztum, J. L., Tsimikas, S., & Nordestgaard, B. G. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.308761 · Cited by 81
Najjar, R. S., Moore, C. E., & Montgomery, B. D. (2018) · Clinical Cardiology · doi:10.1002/clc.23027 · Cited by 87
“Elevated Lp(a) is independently associated with cardiovascular disease,(4) and the LPA gene was observed to have the strongest genetic link to cardiovascular disease.(5) Individuals with Lp(a) plasma concentrations >20 mg/dL have”
BackgroundTada, H., Kawashiri, M.-A., Yoshida, T., Teramoto, R., Nohara, A., Konno, T., Inazu, A., Mabuchi, H., Yamagishi, M., & Hayashi, K. (2016) · Circulation Journal · doi:10.1253/circj.cj-15-0999 · Cited by 79
Kumar, P., Swarnkar, P., Misra, S., & Nath, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-95141-0 · Cited by 83
Genome-Wide Association Study of Peripheral Artery Disease
van Zuydam, N. R., Stiby, A., Abdalla, M., Austin, E., Dahlström, E. H., McLachlan, S., Vlachopoulou, E., Ahlqvist, E., Di Liao, C., Sandholm, N., et al. (2021) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.119.002862 · Cited by 80
Self-citationLeibundgut, G., Arai, K., Orsoni, A., Yin, H., Scipione, C., Miller, E. R., Koschinsky, M. L., Chapman, M. J., Witztum, J. L., & Tsimikas, S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.033 · Cited by 80
Deo, R. C., Wilson, J. G., Xing, C., Lawson, K., Kao, W. H. L., Reich, D., Tandon, A., Akylbekova, E., Patterson, N., Mosley, T. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014581 · Cited by 77
“We estimate that common LPA variants explain 73613% of this ancestry association. rs9457951 Is Strongly Associated with Isoform-adjusted Lp(a) Levels in an Independent Population To validate our results in an independent population, we genotyped rs9457951 in 1,726 African Americans and 996 European Americans in DHS, a…”
BackgroundInfluentialWhen should we measure lipoprotein (a)?
Kostner, K. M., Marz, W., & Kostner, G. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht053 · Cited by 77
Hoekstra, M., Chen, H. Y., Rong, J., Dufresne, L., Yao, J., Guo, X., Tsai, M. Y., Tsimikas, S., Post, W. S., Vasan, R. S., et al. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.314965 · Cited by 80
Zheng, S., Tsao, P. S., & Pan, C. (2024) · Nature Communications · doi:10.1038/s41467-024-49921-7 · Cited by 83
Genetics of Lipid and Lipoprotein Disorders and Traits
Dron, J. S., & Hegele, R. A. (2016) · Current Genetic Medicine Reports · doi:10.1007/s40142-016-0097-y · Cited by 77
“Recent meta-analyses in case-control studies using SNPs at the LPA locus on chromosome 6q25-26 confirm association with CHD [81].”
MethodMolecular Biomarkers for Cardiometabolic Disease: Risk Assessment in Young Individuals
Tahir, U. A., & Gerszten, R. E. (2023) · Circulation Research · doi:10.1161/circresaha.123.322000 · Cited by 82
Molecular genetics of coronary artery disease
Ozaki, K., & Tanaka, T. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.70 · Cited by 86
Heterozygous ATP-binding Cassette Transporter G5 Gene Deficiency and Risk of Coronary Artery Disease
Nomura, A., Emdin, C., Won, H., Peloso, G., Natarajan, P., Ardissino, D., Danesh, J., Schunkert, H., Correa, A., Bown, M., et al. (2019) · bioRxiv · doi:10.1161/circgen.119.002871 · Cited by 39
Self-citationHuffman, J. E., de Vries, P. S., Morrison, A. C., Sabater‐Lleal, M., Kacprowski, T., Auer, P. L., Brody, J. A., Chasman, D. I., Chen, M., Guo, X., et al. (2015) · Blood · doi:10.1182/blood-2015-02-624551 · Cited by 84
Self-citationRotger, M., Glass, T. R., Junier, T., Lundgren, J. D., Neaton, J. D., Poloni, E. S., Wout, A. B. V. ’., Lubomirov, R., Colombo, S. F., Martínez, R., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit196 · Cited by 79
“genetic variants that contribute to the risk of CAD in the general population [15, 16].”
BackgroundSmall, A. M., Peloso, G. M., Linefsky, J., Aragam, J., Galloway, A., Tanukonda, V., Wang, L.-C., Yu, Z., Sunitha Selvaraj, M., Farber-Eger, E. H., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.061451 · Cited by 76
Trinder, M., DeCastro, M. L., Azizi, H., Cermakova, L., Jackson, L. M., Frohlich, J., Mancini, G. B. J., Francis, G. A., & Brunham, L. R. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.065 · Cited by 76
Genetics and Pathophysiological Mechanisms of Lipoprotein(a)‐Associated Cardiovascular Risk
Volgman, A. S., Koschinsky, M. L., Mehta, A., & Rosenson, R. S. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033654 · Cited by 80
Personalized medicine: hope or hype?
Salari, K., Watkins, H., & Ashley, E. A. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs112 · Cited by 70
“Early studies have noted that common CNVs account for only a limited proportion of heritability,(43,44) yet some notable examples exist.(45) Future efforts should examine a broader range of structural variation including those that are individually rare yet in aggregate implicate specific genes.”
BackgroundSelf-citationThe burden of hypercholesterolemia and ischemic heart disease in an ageing world
Pirillo, A., & Norata, G. D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106814 · Cited by 75
Dzobo, K. E., Cupido, A. J., Mol, B. M., Stiekema, L. C. A., Versloot, M., Winkelmeijer, M., Peter, J., Pennekamp, A.-M., Havik, S. R., Vaz, F. M., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319937 · Cited by 76
In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a)
Frischmann, M. E., Ikewaki, K., Trenkwalder, E., Lamina, C., Dieplinger, B., Soufi, M., Schweer, H., Schaefer, J. R., König, P., Kronenberg, F., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.09.031 · Cited by 75
“Depending on the used genetic approach, it has been shown that between 30% and 90% of this variation in plasma Lp(a) concentration is determined by the apo(a) gene locus, encoding proteins from<300 to>800 kDa [2,3].”
MethodThe impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk
Reyes‐Soffer, G. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000753 · Cited by 77
Metadata
- Authors
- Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., Bennett, D., Silveira, A., Malarstig, A., Green, F. R., Lathrop, M., Gigante, B., Leander, K., de Faire, U., Seedorf, U., Hamsten, A., Collins, R., Watkins, H., & Farrall, M.
- Affiliations
- University of Oxford (GB)
- Centre for Human Genetics (GB)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Mario Negri Institute for Pharmacological Research (IT)
- University of Münster (DE)
- University of Surrey (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-24
- Volume
- 361
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2098230963
- Cited by
- 1,671
- References
- 40
- Citations by year
- 2026: 129 · 2025: 134 · 2024: 121 · 2023: 124 · 2022: 133 · 2021: 103 · 2020: 101 · 2019: 96 · 2018: 75 · 2017: 90 · 2016: 103 · 2015: 90 · 2014: 82 · 2013: 73 · 2012: 88
- FWCI
- 73.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Funders
- Wellcome Trust
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- coronary artery disease, LPA gene, single nucleotide polymorphisms, rs10455872, rs3798220, genetic association, 9p21
- MeSH terms
- Coronary Disease, Genetic Markers, Genotype, Humans, Myocardial Infarction, Regression Analysis, Risk Factors, Likelihood Functions, Case-Control Studies, Lipoprotein(a), Kringles, Genetic Predisposition to Disease, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.